Hectorol doxercalciferol capsules: Phase III data; marketed to treat secondary hyperparathyroidism in end-stage renal disease

In a 30-patient Phase III study, BCII said that 24 weeks of Hectorol treatment gave a 60 percent reduction in parathyroid hormone levels with no adverse events or impairment of renal function. Data w...